Loading...
Market
What will be the next major milestone for Centessa ($CNTA) ORX750 by September 30, 2025?
2
Resolution / Starting Odds
Phase 2 Completion • 25%
Partnership/Acquisition • 25%
FDA Approval • 25%
Other • 25%
Official press release from Centessa Pharmaceuticals or clinical trial registry
Story
Centessa ($CNTA) Hits Three-Year High on Positive Phase 1 Data for ORX750
Sep 10, 2024, 02:21 PM
Centessa Pharmaceuticals ($CNTA) has announced positive interim Phase 1 clinical data for its novel Orexin Receptor 2 (OX2R) agonist, ORX750. The study involved acutely sleep-deprived healthy volunteers and has shown promising results. This development has propelled Centessa's stock to a three-year high, highlighting a significant $5 billion opportunity in the narcolepsy market. The milestone was celebrated by the Centessa team, including Mario Accardi.
View original story
Similar markets
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
FDA Approval • 25%
EMA Approval • 25%
Phase 4 Trial Initiation • 25%
Other • 25%
Initiate clinical trial • 25%
Secure additional funding • 25%
Enter partnership • 25%
Other • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
Phase 2 Trial Completion • 25%
FDA Approval • 25%
Commercial Launch • 25%
None of the Above • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Phase 3 trial initiation • 25%
FDA Breakthrough Therapy designation • 25%
Partnership announcement • 25%
No major milestone • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%